CRISPR Therapeutics AG’s recently made public that its Chief Operating Officer Bruno Julianne unloaded Company’s shares for reported $0.19 million on Jun 21 ’24. In the deal valued at $56.09 per share,3,366 shares were sold. As a result of this transaction, Bruno Julianne now holds 6,745 shares worth roughly $0.39 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Kulkarni Samarth sold 19,582 shares, generating $1,173,232 in total proceeds. Upon selling the shares at $59.91, the Chief Executive Officer now owns 208,122 shares.
Before that, Kulkarni Samarth sold 20,000 shares. CRISPR Therapeutics AG shares valued at $1,449,628 were divested by the Chief Executive Officer at a price of $72.48 per share. As a result of the transaction, Kulkarni Samarth now holds 208,122 shares, worth roughly $12.18 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid February with a ‘”a Peer perform”‘ rating. TD Cowen also remained covering CRSP and has decreased its forecast on December 11, 2023 with a “an Underperform” recommendation from previously “Market perform” rating. Cantor Fitzgerald revised its rating on October 17, 2023. It rated CRSP as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of CRSP
On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 1.00% to $58.50. Over the last five days, the stock has gained 4.02%. CRISPR Therapeutics AG shares have fallen nearly -6.55% since the year began. Nevertheless, the stocks have risen 2.13% over the past one year. While a 52-week high of $91.10 was reached on 02/22/24, a 52-week low of $37.55 was recorded on 05/10/24. SMA at 50 days reached $57.21, while 200 days put it at $61.55. A total of 0.8 million shares were traded, compared to the trading of 0.87 million shares in the previous session.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 56.98, which if violated will result in even more drops to 55.45. On the upside, there is a resistance level at 59.55. A further resistance level may holdings at 60.59. The Relative Strength Index (RSI) on the 14-day chart is 53.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.57%. Stochastics%K at 45.68% indicates the stock is a holding.
The most recent change occurred on September 27, 2023 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $82 price target.
